Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

Slides:

Advertisements

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Advertisements

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

The SPRINT Research Group

Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy Wilson Y.S. Leung, BPharm, PhD, Wing-Yee.

New-onset Atrial Fibrillation Predicts Heart Failure Progression

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

The Diabetes Shared Care Program and Risks of Cardiovascular Events in Type 2 Diabetes Edy Kornelius, MD, Jeng-Yuan Chiou, PhD, Yi-Sun Yang, PhD, MD,

Discharge Heart Rate and Mortality after Acute Myocardial Infarction

Masaya Koshizaka, MD, PhD, Renato D. Lopes, MD, PhD, MHS, L

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review Shelley R. Salpeter, MD, Jacob S.

Brian Radbill, MD, Barbara Murphy, MD, Derek LeRoith, MD, PhD

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Bertha Wong, MD, Muhammad M. Mamdani, PharmD, MPH, Catherine H

Introduction The American Journal of Medicine

Matthew I. Worthley, MBBS, PhD, FRACP, Fiona M

Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease.

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Trends in Stroke Rates, Risk, and Outcomes in the United States, 1988 to 2008 Margaret C. Fang, MD, MPH, Marcelo Coca Perraillon, MA, Kaushik Ghosh, PhD,

Prognostic Importance of Low Admission Serum Creatinine Concentration for Mortality in Hospitalized Patients Charat Thongprayoon, MD, Wisit Cheungpasitporn,

Body Mass Index and Mortality in Acute Myocardial Infarction Patients

The Impact of Race on the Prognosis of Preclinical Diastolic Dysfunction: A Large Multiracial Urban Population Study Jian Shan, MD, Lili Zhang, MD, MSc,

Laura Sarkisian, MD, Lotte Saaby, MD, PhD, Tina S

Cardiovascular Disease and CKD: Core Curriculum 2010

Robert Goulden, MBBS, MSc, MPhil, MA The American Journal of Medicine

Periodontal Pocket Depth, Hyperglycemia, and Progression of Chronic Kidney Disease: A Population-Based Longitudinal Study Jia-Feng Chang, MD, Jih-Chen.

Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction Victoria Hamill, PhD, Ian Ford, PhD, Kim Fox, MD,

Adherence to Secondary Prevention Medications and Four-year Outcomes in Outpatients with Atherosclerosis Dharam J. Kumbhani, MD, SM, MRCP, Ph. Gabriel.

Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation Nasir Shariff, MD, Ravi V. Desai, MD, Kanan Patel,

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

The Reply The American Journal of Medicine

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial Daniel H. Solomon, MD, MPH, M. Elaine.

Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G

Syncope: Outcomes and Conditions Associated with Hospitalization

Association of Serum Magnesium on Mortality in Patients Admitted to the Intensive Cardiac Care Unit Niyada Naksuk, MD, Tiffany Hu, BS, Chayakrit Krittanawong,

Interaction of Physical Activity and Body Mass Index on Mortality in Coronary Heart Disease: Data from the Nord-Trøndelag Health Study Trine Moholdt,

Focusing on Health Literacy Might Help Us Cross the Quality Chasm

The Impact of Prior Heart Failure Hospitalizations on Long-term Mortality Differs by Baseline Risk of Death Naga V.A. Kommuri, MD, Todd M. Koelling,

Molly E. Waring, PhD, Jane S

Glycemic Status and Mortality in Chronic Kidney Disease According to Transition Versus Nontransition to Dialysis Connie M. Rhee, MD, MSc, Csaba P. Kovesdy,

Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease Johannes F.E. Mann, Qi-Long.

On Statin Treatment to Prevent Sepsis in Dialysis Patients

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with.

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Beef Tea, Vitality, Creatinine, and the Estimated GFR

Christina L. Klein, MD, Daniel C. Brennan, MD, FACP

Estimated Glomerular Filtration Rate Within the Normal or Mildly Impaired Range and Incident Cardiovascular Disease Alon Eisen, MD, Moshe Hoshen, PhD,

MATCH Results: Implications for the Internist

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Angiotensin-converting Enzyme Inhibitors and Outcomes in Heart Failure and Preserved Ejection Fraction Marjan Mujib, MD, MPH, Kanan Patel, MBBS, MPH,

Volume 65, Issue 4, Pages (April 2004)

Ali Ahmed, MD, MPH, Michael W. Rich, MD, Michael Zile, MD, Paul W

John-Michael Gamble, BScPharm, MSc, Dean T. Eurich, PhD, Thomas J

Devraj Sukul, MD, Shashank S. Sinha, MD, MSc, Andrew M

Volume 80, Issue 6, Pages (September 2011)

Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus James H. O'Keefe, MD, Mohammad Abuannadi,

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex Naji Kholaif,

Volume 87, Issue 3, Pages (March 2015)

Higher Cardiovascular Disease Prevalence and Mortality among Younger Blacks Compared to Whites Stacey Jolly, MD, MS, Eric Vittinghoff, PhD, Arpita Chattopadhyay,

Daniel E. Weiner, MD, MS, Hocine Tighiouart, MS, John L

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Significance of Comorbid Psychological Stress and Depression on Outcomes After Cardiac Rehabilitation Sergey Kachur, MD, Arthur R. Menezes, MD, Alban.

Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy Wilson Y.S. Leung, BPharm, PhD, Wing-Yee.

Sex Differences in the Management and 5-Year Outcome of Young Patients (

Presentation transcript:

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric S. Nylen, MD, Michael Doumas, MD, Jeff Probstfield, MD, Johannes F.E. Mann, MD, Richard E. Gilbert, MD, Hertzel C. Gerstein, MD, MSc The American Journal of Medicine Volume 130, Issue 12, Pages 1465.e27-1465.e39 (December 2017) DOI: 10.1016/j.amjmed.2017.05.047 Copyright © 2017 Terms and Conditions

Figure 1 (A) Rates and hazard ratios (HRs) of primary and secondary outcomes in patients with and without chronic kidney disease (CKD), adjusted for treatment allocation, glycemic status, and prior cardiovascular event. (B) HRs for the primary outcome for patients with and without CKD in all prespecified subgroups, adjusted for treatment allocation, glycemic status, and prior cardiovascular event. CV = cardiovascular; DCCT = Diabetes Control + Complications Trial; HF = heart failure; MI = myocardial infarction. The American Journal of Medicine 2017 130, 1465.e27-1465.e39DOI: (10.1016/j.amjmed.2017.05.047) Copyright © 2017 Terms and Conditions

Figure 2 (A) Kaplan-Meier curves for the primary outcome among participants without chronic kidney disease (CKD), CKD stage 1 and 2, and CKD stage 3. (B) Kaplan-Meier curves for all-cause mortality among participants without CKD, CKD stage 1 and 2, and CKD stage 3. (C) Kaplan-Meier curves for cardiovascular mortality among participants without CKD, CKD stage 1 and 2, and CKD stage 3. The American Journal of Medicine 2017 130, 1465.e27-1465.e39DOI: (10.1016/j.amjmed.2017.05.047) Copyright © 2017 Terms and Conditions

Supplementary Figure (A) Rates and hazard ratios (HRs) (95% confidence intereval [CI]) of primary and secondary outcome in patients with and without chronic kidney disease (CKD) adjusted for albuminuria, treatment allocation, glycemic status, and prior cardiovascular event. (B) HRs for primary outcome for all prespecified subgroups of patients with and without CKD adjusted for albuminuria, treatment allocation, glycemic status, and prior cardiovascular event. The American Journal of Medicine 2017 130, 1465.e27-1465.e39DOI: (10.1016/j.amjmed.2017.05.047) Copyright © 2017 Terms and Conditions